Showing 5551-5560 of 10114 results for "".
- Prestige Beauty Industry Grows to $17.7Bhttps://practicaldermatology.com/news/prestige-beauty-industry-grows-to-177b/2457900/The US prestige beauty industry reached $17.7 billion in 2017, a six percent increase over 2016, according to global information company The NPD Group. The skincare category led in growth with a nine percent increase in sales that contributed 45 percent of t
- Water Baths As Effective As Bleach Baths for Eczemahttps://practicaldermatology.com/news/water-baths-as-effective-as-bleach-baths-for-eczema/2457967/Water baths are as good as bleach baths for treating eczema, and they are safer, finds a new Northwestern Medicine study. Bleach baths can cause stinging and burning of skin, and occasionally even trigger asthma flare-ups in patients. “I don’t know if it throws the bab
- 23andMe Data Helps ID BCC Risk Geneshttps://practicaldermatology.com/news/23andme-data-helps-id-bcc-risk-genes/2458459/New research out of 23andMe and Stanford University School of Medicine pinpoints 31 genetic associations for basal cell carcinoma (BCC), 14 of which are all new. Taken together, these associations are estimated to explain almost 11 percent of the genetic risk for BCC, according to t
- FDA Proposes Ban on Most Powdered Medical Gloveshttps://practicaldermatology.com/news/fda-proposes-ban-on-most-powdered-medical-gloves/2458639/The FDA has proposed a ban on most powdered gloves in the United States. While use of these gloves is decreasing, they pose an unreasonable and substantial risk of illness or injury to health care providers, patients and other individuals who are exposed to them, which cannot be corrected t
- ChloraDerm Launches Pediatric Offeringhttps://practicaldermatology.com/news/chloraderm-launches-pediatric-offering/2458683/entrotech life sciences (ELS) announced the availability of FDA-Cleared ChloraDerm in a new 1.75"x 1.75" configuration, ideal for pediatric patient use. ChloraDerm is the only transparent film dressing containing the Chlorhexidine Advantage, a safe, colophony-and acid-free, edge-t
- BTL Vanquish FDA Cleared for Circumferential Reduction of Abdomen Areahttps://practicaldermatology.com/news/btl-vanquish-fda-cleared-for-circumferential-reduction-of-abdomen-area/2458926/BTL Industries received FDA clearance of its BTL Vanquish device for circumferential reduction of the abdomen area. BTL Vanquish uses a panel array that emits selective RF energy with the largest spot size in the industry t
- European Commission Grants Conditional Approval to Erivedgehttps://practicaldermatology.com/news/20130716-european_commission_grants_conditional_approval_to_erivedge/2459497/The European Commission has granted conditional approval to Erivedge (vismodegib) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy. The Commission granted the conditional approval based upon t
- Free Podcasts on Complete UV Protectionhttps://practicaldermatology.com/news/20120612-free_podcasts_on_complete_uv_protection/2459785/On the new edition of "Healthy Vision with Dr. Val Jones," dermatologist and author Jeanine Downie, MD, and Stephen Cohen, OD, past president of the Arizona Optometric Association, join Dr. Val to talk about the importance of sun protection. Both doctors share tips on steps adults and children can t
- Warning for Blood Clot Risk Added to Drospirenone OCPshttps://practicaldermatology.com/news/20120411-warning_for_blood_clot_risk_added_to_drospirenone_ocps/2459827/The U.S. Food and Drug Administration (FDA) has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. Drospirenone is a synthetic version of the female hormone, progesterone, also referred t
- Study: Questionable Efficacy for Complementary and Alternative Skin Care Therapieshttps://practicaldermatology.com/news/study-evaluates-efficacy-of-alternative-therapies-in-skin-care/2475123/Complementary and alternative medicines (CAMs) commonly used in dermatology lack high-quality evidence needed to support their efficacy, according to a comprehensive literature review from researchers at Baylor College of Medicine.